Sign in

Research summary ·

Cytomegalovirus infection in patients receiving bispecific antibodies for multiple myeloma and B-cell malignancies: a single-center cohort and meta-analysis.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This study looked at cytomegalovirus (CMV) infection in people on bispecific antibodies. These drugs treat myeloma and B-cell cancers. The work had a local cohort and a meta-analysis. The cohort came from the team's own center, 2020 to 2025. The team also pooled trials and other studies. It tracked clinically significant CMV infection, CMV DNA in blood and CMV disease.

What they found

The local cohort had 98 treatment courses. Follow-up was 10.4 months. Significant infection occurred in 9 of 98 courses. CMV disease occurred in 3 of 98. Risk factors included poor fitness and past stem cell transplant. They also included grade 4 neutropenia and severe cytokine release syndrome. The meta-analysis pooled 23 studies plus the cohort, for 2,956 courses. Pooled rates were low for both. They were higher where studies routinely checked CMV DNA. They were also higher with anti-BCMA drugs.

What it means for patients

The team says significant CMV infection and CMV disease are uncommon here. They say this argues against routine CMV checks or antiviral prevention. They say prevention may be warranted with anti-BCMA drugs when added risks exist. Examples are transplant or severe cytokine release syndrome.

Why it is not certain yet

The cohort looked back at past records. Results differed a lot between studies. The risk factors came from univariable analysis. The abstract says routine monitoring raised the rates found.

Source

Cytomegalovirus infection in patients receiving bispecific antibodies for multiple myeloma and B-cell malignancies: a single-center cohort and meta-analysis.

PubMed · PMID 42718550

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Multiple myeloma publications